Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd grew its position in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 26.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 41,244 shares of the biopharmaceutical company’s stock after acquiring an additional 8,546 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in Gilead Sciences were worth $2,452,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Gilead Sciences by 2.3% in the 1st quarter. BlackRock Inc. now owns 121,709,365 shares of the biopharmaceutical company’s stock valued at $7,235,622,000 after purchasing an additional 2,748,159 shares in the last quarter. State Street Corp lifted its stake in shares of Gilead Sciences by 1.0% in the 1st quarter. State Street Corp now owns 57,970,959 shares of the biopharmaceutical company’s stock valued at $3,446,374,000 after purchasing an additional 601,690 shares in the last quarter. Capital World Investors lifted its stake in shares of Gilead Sciences by 15.4% in the 4th quarter. Capital World Investors now owns 42,681,624 shares of the biopharmaceutical company’s stock valued at $3,099,157,000 after purchasing an additional 5,705,315 shares in the last quarter. Geode Capital Management LLC lifted its position in Gilead Sciences by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 22,739,179 shares of the biopharmaceutical company’s stock worth $1,647,123,000 after acquiring an additional 440,695 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after acquiring an additional 13,764,169 shares in the last quarter. 78.58% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $65.28 on Monday. The business’s 50 day moving average is $62.73 and its two-hundred day moving average is $61.77. Gilead Sciences, Inc. has a 52-week low of $57.17 and a 52-week high of $74.12. The firm has a market cap of $81.82 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 0.67 and a beta of 0.31. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.30.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Thursday, September 15th will be issued a $0.73 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.47%. Gilead Sciences’s dividend payout ratio (DPR) is 89.02%.

Wall Street Analyst Weigh In

Several research firms recently commented on GILD. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, July 12th. They set a “neutral” rating and a $70.00 price target on the stock. BMO Capital Markets began coverage on Gilead Sciences in a research report on Tuesday, June 7th. They set a “hold” rating and a $63.00 price target on the stock. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Monday, August 15th. SVB Leerink began coverage on Gilead Sciences in a research report on Monday, May 23rd. They set a “market perform” rating and a $68.00 price target on the stock. Finally, Morgan Stanley boosted their price target on Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $72.40.

Gilead Sciences Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.